Clinical Trials in Rialto, California
13 recruiting
Showing 1–13 of 13 trials
Recruiting
Phase 2
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
Metabolic dysfunction-associated steatohepatitis (MASH)
Regeneron Pharmaceuticals120 enrolled71 locationsNCT05519475
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
89bio, Inc.762 enrolled296 locationsNCT06419374
Recruiting
Phase 1
A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234
Hepatic Impairment
AstraZeneca28 enrolled4 locationsNCT07546760
Recruiting
Phase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
89bio, Inc.1,350 enrolled342 locationsNCT06318169
Recruiting
Phase 2
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
Overweight or Obesity and Elevated Liver Fat
Amgen180 enrolled18 locationsNCT07441252
Recruiting
Phase 2
A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)
Chronic Hepatitis B Infection
Aligos Therapeutics200 enrolled58 locationsNCT06963710
Recruiting
Phase 3
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Metabolic dysfunction-associated steatohepatitis (MASH)Liver Fibrosis
Boehringer Ingelheim1,800 enrolled524 locationsNCT06632444
Recruiting
Phase 3
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Metabolic Dysfunction-Associated Steatohepatitis
Boehringer Ingelheim1,590 enrolled443 locationsNCT06632457
Recruiting
Phase 1
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
Moderate Hepatic Impairment
AstraZeneca20 enrolled2 locationsNCT07343960
Recruiting
Phase 1
A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
Non-Alcoholic Fatty Liver Disease
GlaxoSmithKline32 enrolled3 locationsNCT07358546
Recruiting
Phase 2
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
Metabolic Dysfunction-Associated Steatohepatitis
Boston Pharmaceuticals42 enrolled35 locationsNCT06920043
Recruiting
Phase 1
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
CirrhosisHepatic Impairment
Vir Biotechnology, Inc.144 enrolled5 locationsNCT05484206
Recruiting
Phase 1
A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function
Hepatic Insufficiency
X4 Pharmaceuticals48 enrolled4 locationsNCT06858696